195 related articles for article (PubMed ID: 1835818)
1. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells.
Knabbe C; Zugmaier G; Schmahl M; Dietel M; Lippman ME; Dickson RB
Am J Clin Oncol; 1991; 14 Suppl 2():S15-20. PubMed ID: 1835818
[TBL] [Abstract][Full Text] [Related]
2. Preclinical data for Droloxifene.
Hasmann M; Rattel B; Löser R
Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic and biologic properties of droloxifene, a new antiestrogen.
Eppenberger U; Wosikowski K; Küng W
Am J Clin Oncol; 1991; 14 Suppl 2():S5-14. PubMed ID: 1962598
[TBL] [Abstract][Full Text] [Related]
4. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Müller V; Jensen EV; Knabbe C
Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.
Yao D; Zhang F; Yu L; Yang Y; van Breemen RB; Bolton JL
Chem Res Toxicol; 2001 Dec; 14(12):1643-53. PubMed ID: 11743747
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
Simard J; Labrie C; Bélanger A; Gauthier S; Singh SM; Mérand Y; Labrie F
Int J Cancer; 1997 Sep; 73(1):104-12. PubMed ID: 9334816
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
[TBL] [Abstract][Full Text] [Related]
9. Regulation and role of TGF beta production in breast cancer.
Knabbe C; Kopp A; Hilgers W; Lang D; Müller V; Zugmaier G; Jonat W
Ann N Y Acad Sci; 1996 Apr; 784():263-76. PubMed ID: 8651574
[TBL] [Abstract][Full Text] [Related]
10. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of nitric oxide production by droloxifene and toremifene in human breast cancer cells.
Martin JH; Symonds A; Chohan S
Oncol Rep; 2003; 10(4):979-84. PubMed ID: 12792756
[TBL] [Abstract][Full Text] [Related]
12. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
Herman ME; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
[TBL] [Abstract][Full Text] [Related]
13. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells).
Styles JA; Davies A; Davies R; White IN; Smith LL
Carcinogenesis; 1997 Feb; 18(2):303-13. PubMed ID: 9054622
[TBL] [Abstract][Full Text] [Related]
14. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines.
Néri C; Berthois Y; Schatz B; Drieu K; Martin PM
Breast Cancer Res Treat; 1990 Feb; 15(2):85-93. PubMed ID: 2138918
[TBL] [Abstract][Full Text] [Related]
15. Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells.
Koli KM; Ramsey TT; Ko Y; Dugger TC; Brattain MG; Arteaga CL
J Biol Chem; 1997 Mar; 272(13):8296-302. PubMed ID: 9079651
[TBL] [Abstract][Full Text] [Related]
16. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
17. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogen therapy for breast cancer: current strategies and future prospects.
Jordan VC; Tormey DC
Cancer Treat Res; 1988; 39():97-110. PubMed ID: 2908611
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.
Wärri AM; Huovinen RL; Laine AM; Martikainen PM; Härkönen PL
J Natl Cancer Inst; 1993 Sep; 85(17):1412-8. PubMed ID: 8350365
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and antiestrogen actions on transforming growth factorbeta (TGFbeta) in normal human breast epithelial (HBE) cells.
Malet C; Fibleuil F; Mestayer C; Mowszowicz I; Kuttenn F
Mol Cell Endocrinol; 2001 Mar; 174(1-2):21-30. PubMed ID: 11306168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
